


PHARMACEUTICAL 2019

ORAMED

ORAMED PHARMACEUTICALS INC. Rank 116 of 371





PHARMACEUTICAL 2019

ORAMED PHARMACEUTICALS INC. Rank 116 of 371



The relative strengths and weaknesses of ORAMED PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ORAMED PHARMACEUTICALS INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 75% points. The greatest weakness of ORAMED PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is -53%, being 278% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	31,037
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,553
Liabilities, Non-Current	11,732
Other Assets	16,343
Other Compr. Net Income	301
Other Expenses	17
Other Liabilities	0
Other Net Income	0
Property and Equipment	17
Research and Development	11,979
Revenues	3,352
Selling, General and Administrative Expense	4,083

Output Variable	Value in 1000 USD
Assets	47,397
Liabilities	16,285
Expenses	16,079
Stockholders Equity	31,112
Net Income	-12,727
Comprehensive Net Income	-12,576
Economic Capital Ratio	-53%